ETV6 Sequencing Important Among Patients With Inherited Thrombocytopenia, Malignancy
It may be important to sequence ETV6in patients with inherited thrombocytopenia or malignancy and to schedule regular follow-ups to check for secondary cancers.
Thrombotic Disorders
Obesity in Adolescent Men Associated With Increased Risk for Later VTE
Obesity in early adulthood is associated with increased risk for venous thromboembolism later in life, especially pulmonary embolism.
DOACs May Increase Risk of Bleeding Complications in Severe COVID-19 Cases
Replacing DOACs with alternative parenteral antithrombotic strategies may help to prevent bleeding complications in patients with SARS-CoV-2 infection.
Clotting and COVID: New Guidelines in the Works to Treat Coagulopathies in Patients With COVID-19
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Anticoagulation May Improve Outcomes in COVID-19 Patients
Longer duration of AC treatment linked to reduced risk for mortality in hospitalized patients.
Patterns of Anticoagulant Therapy Use for Acute Venous Thromboembolism
Investigators compared the use of DOACs with traditional therapies in patients with acute VTE who were either discharged directly from the ED or hospitalized.
High Incidence of Thrombotic Complications in Patients With COVID-19
Investigators assessed rates of VTE and arterial thrombotic complications in patients admitted to the ICU with COVID-19 infection.
Venous Thromboembolism vs Major Bleeding: Case Fatality Rates of Patients With Cancer Receiving Anticoagulation
Case fatality rates may vary among cancer patients with VTE or major bleeding who receive anticoagulant treatments.
Bleeding Risk Assessed With Concomitant Direct Oral Anticoagulants and Verapamil or Diltiazem
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
Apixaban Noninferior to Dalteparin for Treatment of Cancer-Associated Venous Thromboembolism
Oral apixaban is noninferior to subcutaneous dalteparin for the treatment of cancer-linked VTE without increasing the risk of major bleeding.
Next post in Thrombotic Disorders
